Home | Business News | Browse by Publication | B | Biotech Business

FDA LIFTS PARTIAL CLINICAL HOLD OF ICA-105665.

Publication: Biotech Business
Publication Date: 01-SEP-09
Format: Online
Delivery: Immediate Online Access

Article Excerpt
Icagen, Inc. (Nasdaq:ICGN), Research Triangle Park, N.C., has reported that the FDA has lifted the partial clinical hold related to the development of ICA-105665, the company's novel orally available small molecule KCNQ potassium channel agonist, for the treatment of epilepsy. Accordingly, the company is planning to initiate a proof-of-concept study in patients with photosensitive epilepsy.

The photosensitive epilepsy study was designed with international experts including members of the Epilepsy Study Consortium and will be conducted at multiple clinical research centers in the U.S....

Access Full Article, Compliments of Goliath



More articles from Biotech Business
FDA APPROVES AVASTIN FOR THE MOST COMMON KIDNEY CANCER., September 01, 2009

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.